Lonza lifts mid-term targets for Lonza Group stock

Published on 10/21/2026 at 09:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Lonza targets 10-13 percent organic growth over time. Lonza Group stock costs EUR 670.50 on October 21, 2026 as 2026 margin guidance stays at 33-34 percent.

Growth targets and valuation context

Lonza upgraded its organic growth model on October 14, 2026.
The company confirmed 11-12 percent sales growth and a 33-34 percent core EBITDA margin for 2026.
Lonza Group stock trades at EUR 670.50 at 9:36 a.m. CEST at Lang & Schwarz on October 21, 2026.

Pop-Art-Comic: Stilisierte Kapsel-Pille mit Halftone-Punkten und leerer Comic-Sprechblase — Lonza CH0013841017 Pop Art Comic Pille mit Halftone Punkten und leerer Comic Sprechblase, Illustration mit AI erstellt.

Lonza Group (ISIN CH0013841017) was trading at EUR 670.50 at Lang & Schwarz on October 21, 2026 at 9:36 a.m. CEST. On October 14, 2026, Lonza upgraded its medium-term organic growth model and confirmed its full-year outlook.

Targets point to higher margins

The company now targets 10-13 percent organic sales growth at constant exchange rates over time, with core EBITDA growth ahead of sales growth. Its medium-term core EBITDA margin ambition moved into the high-thirties percentage range, while the 2026 target remains 33-34 percent.

Reuters reported on October 14, 2026, that Lonza expected the planned sale of 60 percent of its Capsules and Health Ingredients business to Lone Star Funds to close by the end of 2026. The transaction was agreed at a value of USD 3.00 billion.

What does the guidance mean?

The key distinction is between the 2026 forecast and the longer-term ambition. Lonza confirmed 11-12 percent constant-currency sales growth and a 33-34 percent core EBITDA margin for 2026, while the medium-term model reaches 10-13 percent organic growth and a high-thirties margin. The different periods make execution the central test.

Three dated company steps

On September 30, 2026, Lonza nominated Pearl Huang as one independent board member. On October 12, 2026, it expanded its DNA-to-IND offering, with development timelines of three months for toxicology drug substance and six months for an IND-ready filing, as reported by Boerse Express. On October 14, 2026, Lonza confirmed its third-quarter performance was in line with expectations and set the 10-13 percent medium-term growth model.

The next reporting date

The next substantiated reporting date is January 27, 2027, when Lonza is scheduled to publish its full-year 2026 results, according to Boerse Express. That release will provide the next numerical test of the confirmed outlook.

Stock price and company profile

Lonza's primary listing is on SIX Swiss Exchange, where the stock was trading at CHF 622.20 on October 21, 2026 at 9:28 a.m. CEST. The quote was within the 52-week range of CHF 454.60 to CHF 626.80, while the market capitalization stood at CHF 43.5 billion as of October 21, 2026.

The stock's market value leaves limited room below the reported 52-week high, but the euro reference price and the Swiss listing are separate venue quotations. For investors, the next reporting date matters because the medium-term targets depend on continued delivery in biologics and other contract manufacturing platforms.

Trading snapshot

Lonza Group stock was trading at EUR 670.50 at Lang & Schwarz on October 21, 2026 at 9:36 a.m. CEST. The company remains positioned as a healthcare biotechnology group focused on pharmaceutical and life science manufacturing.

The further course of trading is shown by the continuously updated real-time quote of Lonza Group stock.